Prerequisites, indications and contraindications of IV-Lysis of ischemic stroke with rt-PA;Voraussetzungen, indikationen und kontraindikationen der systemischen lysebehandlung des akuten ischämischen insultes mit rt-PA

Fortschritte der Neurologie Psychiatrie

Volumn 69, Issue 8, 2001, Pages 346-352

  Marx, P ^a   Hartmann, A ^a   Leistner, S ^a   Nohr, R ^a   Koennecke, H C ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE;

ADULT; AGED; ARTICLE; BLEEDING; DRUG EFFICACY; DRUG SAFETY; FIBRINOLYTIC THERAPY; HUMAN; MAJOR CLINICAL STUDY; RATING SCALE; STROKE;

AGED; CEREBRAL HEMORRHAGE; CEREBROVASCULAR ACCIDENT; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 0034870411     PISSN: 07204299     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-16513     Document Type: Article

References (26)

1. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)
2. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)
3. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial
4. Early intravenous thrombolysis for acute ischemic stroke in a community-based approach
5. Intravenous tPA for ischemic stroke team performance over time, safety, and efficacy in a single-center, 2-year experience
6. Transtentorial herniation after unilateral infarction of the anterior cerebral artery
7. Intravenous tissue-type plasminogen activator for treatment of acute stroke: The Standard Treatment with Alteplase to Reverse Stroke (STARS) study
8. Intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 80 years and older: The tPA stroke survey experience
9. Treating acute stroke patients with intravenous tPA. The OSF stroke network experience
10. Urgent therapy for acute stroke. Effects of a stroke trial on untreated patients
11. Effects of public and professional education on reducing the delay in presentation and referral of stroke patients
12. Intravenous tissue plasminogen activator for acute ischemic stroke: Feasibility, safety, and efficacy in the first year of clinical practice
13. Hemorrhagic transformation within 36 hours of a cerebral infarct: Relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort
14. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke
15. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: A secondary analysis of the European-Australasian Acute Stroke Study (ECASS II)
16. Diffusion-weighted MRI as an evolving standard of care in acute stroke
17. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: A randomized controlled trial
18. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): Results of a double-blind, placebo-controlled, multicenter study
19. Early stroke treatment associated with better outcome: The NINDS rt-PA stroke study
20. Intravenous tissue plasminogen activator for acute ischemic stroke: A Canadian hospital's experience
21. Protocol violations in community-based rTPA stroke treatment are associated with symptomatic intracerebral hemorrhage
22. Can emergency department physicians safely and effectively initiate thrombolysis for acute ischemic stroke?
23. Use of tissue-type plasminogen activator for acute ischemic stroke: The Cleveland area experience